Sign up to save your podcasts
Or
Share ACCEL Lite: Featured ACCEL Interview With Eric L. Michelson and Brendan Everett
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ACCEL Lite: Featured ACCEL Interview With Eric L. Michelson and Brendan Everett
In this interview, Eric L. Michelson and Brendan Everett discuss anti-inflammatory therapy with canakinumab and incident type 2 diabetes: a prespecified key secondary endpoint of CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study).
View all episodes
By American College of Cardiology
3.8
5454 ratings
In this interview, Eric L. Michelson and Brendan Everett discuss anti-inflammatory therapy with canakinumab and incident type 2 diabetes: a prespecified key secondary endpoint of CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study).
More shows like ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
View all
JAMA Editors' Summary
139 Listeners
NEJM This Week
319 Listeners
JAMA Clinical Reviews
498 Listeners
JACC This Week
169 Listeners
This Week in Cardiology
884 Listeners
Mayo Clinic Talks
291 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
140 Listeners
Core IM | Internal Medicine Podcast
1,154 Listeners
ACC CardiaCast
40 Listeners
Annals On Call Podcast
195 Listeners
JAMA Medical News
91 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
363 Listeners
Cardionerds: A Cardiology Podcast
429 Listeners
The Curious Clinicians
371 Listeners
Mayo Clinic Cardiovascular CME
32 Listeners